Genetic testing for hereditary cancers can help reduce the risk of cancer

By detecting cancer early, your patient will have access to preventative measures and proactive treatment – leading to an overall better prognosis.

  1. Hereditary Mutations for Oncogenetics

Genetic diagnosis of hereditary cancer

Testing for hereditary cancers can detect specific, heritable, disease-related gene mutations that may increase the risk of certain cancers allowing an in-depth cancer risk assessment for each patient.

The critical goal is to detect cancer early and to give you the opportunity to maximize health outcomes for your patients. Patient-tailored screening programs, preventive measures and proactive treatment are possible for patients of a high-risk group. Early diagnosis can mean a better overall prognosis through a choice of surgical and non-surgical treatment options.


Search our test catalogue


Breast and ovarian cancer

Learn more

Comprehensive cancer panel

Learn more

Methodological summary of CENTOGENE’s hereditary cancer panels

  • Bidirectional NGS sequencing for all genes included in the panels (listed here below).
  • NGS panel analysis with complete 100% coverage for the target regions (technical accuracy of <98.1%).
  • For every panel gene, the complete coding sequence, exon/intron boundaries 10 bp into the intron, relevant promoter gene regions and all HGMD-described pathogenic variants are analyzed, with subsequent variant validation for any clinically relevant genetic variant detected.

Our medical and genetic experts can help determine which genetic testing is right to analyze the risk for hereditary cancer syndromes. After testing, result evaluation and specific recommendations for each individual case are necessary to decide on further steps for full patient care.

Related scientific articles

Breast and ovarian cancer

Breast cancer is one of the most common cancers in the world affecting ~12.5% of women during their lifetime. 5–10% of these patients have a hereditary form.

Mutations in the BRCA1 and BRCA2 genes are the most common hereditary cause. However, other genes such as ATM, BRIP1, CHEK2, PALB2, RAD51, etc. have also been associated with increased risk.

CENTOGENE ID 5046 5246

Gene test:

BRCA1/BRCA2 panel

CentoBreast®

Gene name: BRCA1, BRCA2 ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN, RAD51C, STK11, TP53

Diseases covered:

Breast cancer

Breast cancer, ovarian cancer

Turnaround time: 15 business days 15 business days
How to order: Order a test Order a test

Downloads for BRCA1/BRCA2


Comprehensive cancer panel

CentoCancer® is a specific and sensitive panel with all known highly penetrant cancer genes.

Each gene has been carefully selected based on its risk potential in the development of one of the following cancers: breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer.

CENTOGENE ID 5246

Gene test:

CentoCancer®

Genes name: APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FH, FLCN, HNF1A, HNF1B, HOXB13, MC1R, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NTHL1, PALB2, PMS1, PMS2, POLD1, POLE, POT1, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3
Diseases covered: Breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer
Turnaround time: 15 business days
How to order: Order a test

DOWNLOADS FOR CENTOCANCER®

  • Poster - CentoCancer®

    List of genes and associated cancer types

    Download
  • CentoCancer® - Diagnostic sample report, positive

    Download
  • CentoCancer® - Diagnostic sample report, negative

    Download

Portfolio for hereditary cancer

Single Gene Analysis

Latest scientific articles



Get in touch with our Department of Medical Quality and Counseling

Our consultation service is available in several languages.


+49 (0) 381 - 80113 416

Mon. – Fri. 7 a.m.– 8 p.m. CET • Sat. – Sun. 9 a.m – 5 p.m. CET


For our US customers:

+1 (781) 270 1519

Mon. – Fri. 9 a.m. – 5.30 p.m. EST